Palella F, Baker R, Moorman A, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.PubMedCrossRefGoogle Scholar
Weber R, Sabin C, Friis-Moller N, et al. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med. 2006;166:1632–41.PubMedCrossRefGoogle Scholar
Wyatt C, Malvestutto C, Coca S, et al. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS. 2008;22:1799–807.PubMedCrossRefGoogle Scholar
Peters L, Grint D, Lundgren J, et al. HCV viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS. 2012;26:1917–26.PubMedCrossRefGoogle Scholar
Kakinami L, Block R, Adams M, Cohn S, Maliakkal B, Fisher S. Risk of cardiovascular disease in HIV, hepatitis C or HIV/HCV patients compared to the general population. Int J Clin Pract. 2013;67:6–13.PubMedCrossRefGoogle Scholar
Lo Re V, Teal V, Localio A, et al. Risk of hip fracture associated with HCV infection and HCV/HIV coinfection. Hepatology. 2012;56:1688–98.PubMedCrossRefGoogle Scholar
Soriano V, Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P. Update on HIV/HCV coinfection. Curr HIV/AIDS Rep. 2013. doi:10.1007/s11904-013-0169-5
• Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-HCV coinfected patients. AIDS. 2011;25:2197–208. This article summarises and discusses the major issues that may complicate the use of direct-acting antivirals in hepatitis C patients with HIV infection
Naggie S, Sulkowski M. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 2012;142:1324–34.PubMedCrossRefGoogle Scholar
Barreiro P, Vispo E, Labarga P, et al. Management and treatment of chronic hepatitis C in HIV patients. Semin Liver Dis. 2012;32:138–46.PubMedCrossRefGoogle Scholar
Witt M, Seaberg E, Darilay A, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis. 2013;57:77–84.PubMedCrossRefGoogle Scholar
Sánchez C, Plaza Z, Vispo E, et al. Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. Liver Int. 2013. doi:10.1111/liv.12212
Macías J, Berenguer J, Japón MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with HIV/hepatitis C virus. Hepatology. 2009;50:1056–63.PubMedCrossRefGoogle Scholar
Fernández-Montero JV, Soriano V. Management of hepatitis C in HIV and/or HBV co-infected patients. Best Pract Res Clin Gastroenterol. 2012;26:517–30.PubMedCrossRefGoogle Scholar
Soriano V, Puoti M, García-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1–13.PubMedCrossRefGoogle Scholar
Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P, Soriano V. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-HCV coinfected patients. AIDS. 2013;27:1187–8.PubMedCrossRefGoogle Scholar
Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis. 2007;196:670–6.PubMedCrossRefGoogle Scholar
Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–50.PubMedCrossRefGoogle Scholar
Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839–48.PubMedCrossRefGoogle Scholar
Nuñez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retrovir. 2007;23:972–82.PubMedCrossRefGoogle Scholar
Labarga P, Barreiro P, da Silva A, et al. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-alfa for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. J Infect Dis. 2012;206:961–8.PubMedCrossRefGoogle Scholar
Soriano V, Puoti M, Peters M, et al. Care of patients coinfected with HIV and HCV: 2007 updated recommendations from the HCV-HIV international panel. AIDS. 2007;21:1073–89.PubMedCrossRefGoogle Scholar
EACS guidelines. (www.europeanaidsclinicalsociety.org
). Updated version November 2012.
Medrano J, Neukam K, Rallon N, et al. Modeling the probability of SVR to therapy with pegylated interferon plus ribavirin in patients coinfected with HCV and HIV. Clin Infect Dis. 2010;51:1209–16.PubMedCrossRefGoogle Scholar
Medrano J, de Ledinghen V, Taupin J-L et al. Baseline prediction of response to pegIFN-RBV in chronic hepatitis C using the Prometheus score. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston, Nov 9-13, 2012. Abstract 657.
• Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13:597–605. This is the pivotal study demonstrating the efficacy and safety of boceprevir in coinfected patients
• Sulkowski M, Sherman K, Dieterich D, et al. Telaprevir in combination with peginterferon and ribavirin for chronic HCV genotype 1 infection in HIV-infected patients. Ann Intern Med. 2013. doi:10.7326/0003-4819-159-2-201307160-00654
. This is the pivotal study demonstrating the efficacy and safety of telaprevir in coinfected patients
Hulskotte E, Feng H, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. 2013;56:718–26.PubMedCrossRefGoogle Scholar
van Heeswijk R, Beumont M, Kauffman R, et al. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther. 2013. doi:10.3851/IMP2527
de Kanter C, Blonk M, Colbers A, et al. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis. 2013;56:300–6.PubMedCrossRefGoogle Scholar
Crauwels H, van Heeswijk R, Stevens M, et al. Clinical perspective on drug‑drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013;15:87–101.PubMedGoogle Scholar
Benito JM, Sanchez-Parra C, Barreiro P, et al. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. Antivir Ther. 2013. doi:10.3851/IMP2614
Cachay E, Wyles D, Torriani F, et al. High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based HCV treatment regimen. AIDS. 2013 Jul 24. [Epub ahead of print].
Cotte L, Braun J, Lascoux-Combe C, et al. High early virological response with telaprevir-pegylated interferon-ribavirin in treatment-experienced HCV genotype 1/HIV coinfected patients: ANRS HC26 TelapreVIH study. CROI 2013. March 3-6 2013. Atlanta, GA. Abstract 36.
Poizot-Martin I, Bellissant E, Piroth L, et al. ANRS HC27 BocepreVIH interim analysis: high early virologic response with boceprevir + pegylated interferón + ribavirin in HCV/HCV coinfected patients with previous failure to pegylated interferon + ribavirin. CROI 2013, Atlanta, GA. March 3-6 2013. Abstract 37.
Poveda E, Vispo E, Barreiro P, et al. Predicted effect of direct-acting antivirals in the current HIV-HCV coinfected population in Spain. Antivir Ther. 2012;17:571–5.PubMedCrossRefGoogle Scholar
Vispo E, Rallon N, Labarga P, Barreiro P, Benito JM, Soriano V. Different impact of IL28B polymorphisms on response to peginterferon plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. J Clin Virol. 2012;55:58–61.PubMedCrossRefGoogle Scholar
Barreiro P, Cornelli B, Maida I, et al. Performance of boceprevir or telaprevir in triple therapy with peginterferon and ribavirin in routine clinical practice. EACS. 2013. doi:10.1016/S1473-3099(13)70162-2
Soriano V, Labarga P, Fernández-Montero JV, et al. The changing face of hepatitis C in the new era of direct-acting antivirals. Antivir Res. 2013;97:36–40.PubMedCrossRefGoogle Scholar
Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir with pegylated interferon/ribavirin in patients co-infected with chronic hepatitis C and HIV-1: week-24 interim analysis of the TMC435-C212 study. Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA. Abstract 154LB.
Dieterich D, Soriano V, Nelson M, et al. STARTVerso 4: high rates of early virologic response in hepatitis C virus genotype 1/HIV co-infected patients treated with faldaprevir + pegylated interferon and ribavirin. Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, Georgia. Abstract 40LB.
Rockstroh J, Nelson M, Soriano V, et al. STARTVerso 4 Phase III trial of faldaprevir once-daily plus peginterferon alfa-2a and ribavirin in patients with HIV and HCV genotype 1 coinfection: end of treatment response. EACS, Brussels, Belgium. Oct 2013. (in press).
Sabo J, Kort J, Haschke M, et al. Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers. CROI 2013, Atlanta, GA. March 3-6 2013. Abstract 35.
Scheel T, Rice C. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013;19:837–49.PubMedCrossRefGoogle Scholar
Lok A, Gardiner D, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216–24.PubMedCrossRefGoogle Scholar
Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013. doi:10.1016/j.jhep.2012.09.037
Soriano V, Vispo E, de Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother. 2013;14:1161–70.PubMedCrossRefGoogle Scholar
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.PubMedCrossRefGoogle Scholar
Jacobson I, Gordon S, Kowdley K, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–77.PubMedCrossRefGoogle Scholar
Kowdley K, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype 1 infection (ATOMIC): an open-label, randomized, multicentre phase 2 trial. Lancet. 2013;381:2100–7.PubMedCrossRefGoogle Scholar
Rodriguez-Torres M, Gonzalez A, Rodriguez J, et al. HIV/HCV coinfected and HCV monoinfected patients have similar early HCV viral kinetics with the potent HCV nucleotide polymerase inhibitor sofosbuvir. ICAAC 2012, San Francisco, CA; Sept 9-12 2012 [abstract H-1921a].
Poordad F, Lawitz E, Kowdley K, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368:45–53.PubMedCrossRefGoogle Scholar
Gane E. Future perspectives: towards interferon-free regimens for HCV infection. Antivir Ther. 2012;17:1201–10.PubMedCrossRefGoogle Scholar
Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotypes 1, 2, or 3. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston, November 9-13, 2012. Abstract LB-2.
Kowdley K, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston, November 9-13, 2012. Abstract LB-1.
Zeuzem S, Soriano V, Asselah T, et al. Interferon-free treatment with faldaprevir and BI 207127 for genotype 1 HCV infection. N Engl J Med. 2013;369:630–9.Google Scholar
Cohen M, Chen Y, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.PubMedCrossRefGoogle Scholar
Barreiro P, Duerr A, Beckerman K, Soriano V. Reproductive options for HIV-serodiscordant couples. AIDS Rev. 2006;8:158–70.PubMedGoogle Scholar
Thomas D. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19:850–8.PubMedCrossRefGoogle Scholar
Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR. 2012;61(RR-4):1–32.Google Scholar
Grebely J, Matthews G, Lloyd A, et al. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis. 2013 Jun 27. [Epub ahead of print].
Martin N, Vickerman P, Grebely J, et al. HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013. doi:10.1002/hep.26431
Soriano V, Perelson A, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother. 2008;62:1–4.PubMedCrossRefGoogle Scholar
Ralston R, Jacobson I, Scull M. The conundrum of relapse in STAT-C therapy: does HCV play the Red Queen or Rip Van Winkle? Semin Liver Dis. 2011;31:410–9.PubMedCrossRefGoogle Scholar
Rutter K, Hofer H, Beinhardt S, et al. Durability of SVR in chronic hepatitis C patients treated with peginterferon/ribavirin in combination with a direct-acting antiviral. Aliment Pharmacol Ther. 2013;38:118–23.PubMedCrossRefGoogle Scholar
Lawitz E, Poordad F, Kowdley K, et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol. 2013. doi:10.1016/j.jhep.2013.02.009
Soriano V, Vispo E, de Mendoza C, et al. Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C. Antivir Ther. 2013. doi:10.3851/IMP2659
De Rosa F, Audagnotto S, Bargiacchi O, et al. Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient. J Infect. 2006;53:e215–8.PubMedCrossRefGoogle Scholar
Endo T, Fujimoto K, Nishio M, et al. Case report: clearance of hepatitis C virus after changing the HAART regimen in a patient infected with hepatitis C virus and the HIV. J Med Virol. 2009;81:979–82.PubMedCrossRefGoogle Scholar
Falconer K, Gonzalez V, Reichard O, Sandberg J, Alaeus A. Spontaneous HCV clearance in HCV/HIV-1 coinfection associated with normalized CD4 counts, low level of chronic immune activation and high level of T cell function. J Clin Virol. 2008;41:160–3.PubMedCrossRefGoogle Scholar
Fialaire P, Payan C, Vitour D, et al. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for HIV infection. J Infect Dis. 1999;180:574–5.PubMedCrossRefGoogle Scholar
Perez-Olmeda M, Garcia-Samaniego J, Soriano V. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. AIDS. 2000;14:212.PubMedCrossRefGoogle Scholar
Ranieri R, Santambrogio C, Veronelli A, Pontiroli A. Hepatitis C viremia persistently suppressed by HAART. Clin Infect Dis. 2003;36:1086–7.PubMedCrossRefGoogle Scholar
Torti C, Barnes E, Quiros-Roldan E, Puoti M, Carosi G, Klenerman P. Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection. Antivir Ther. 2004;9:139–42.PubMedGoogle Scholar
Zeitoun J, Mallet V, Chaix ML, Viard J, Blanche S, Pol S. Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy. J Clin Virol. 2007;40:71–3.PubMedCrossRefGoogle Scholar
Weissbrich B, Langmann P, Schubert J, Jassoy C, Klinker H. Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups. Eur J Med Res. 2003;8:495–8.PubMedGoogle Scholar
Manfredi R, Dentale N, Calza L. Spontaneous clearance of chronic hepatitis C infection in a patient with a 20-year-old HIV-hepatitis C co-infection and chronic active hepatitis. Int J STD AIDS. 2012;23:e48–50.PubMedCrossRefGoogle Scholar
Yokozaki S, Takamatsu J, Nakano I, et al. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and HIV: influence of antiretroviral therapy. Blood. 2000;96:4293–9.PubMedGoogle Scholar
Vispo E, Barreiro P, Plaza Z, et al. Spontaneous HCV clearance in HIV patients with chronic hepatitis C on antiretroviral therapy. EACS, Brussels, Belgium. Oct 2013 (in press).
Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A. 2013;110:3991–6.PubMedCrossRefGoogle Scholar